Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Urinary Tract Infection

  Free Subscription


Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    June 2019
  1. MALMROS K, Huttner BD, McNulty C, Rodriguez-Bano J, et al
    Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries - results of an online survey.
    Int J Antimicrob Agents. 2019 Jun 20. pii: S0924-8579(19)30168.
    PubMed     Text format     Abstract available


  2. KONGNAKORN T, Wagenlehner F, Falcone M, Tichy E, et al
    Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
    Int J Antimicrob Agents. 2019 Jun 13. pii: S0924-8579(19)30161.
    PubMed     Text format     Abstract available


    May 2019
  3. GARCIA-FERNANDEZ S, Garcia-Castillo M, Bou G, Calvo J, et al
    Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    Int J Antimicrob Agents. 2019;53:682-688.
    PubMed     Text format     Abstract available


  4. PARVEZ S, Misba L, Ahmad QT, Khan AU, et al
    Emergence of Extremely Drug-Resistant and Uropathogenic New Delhi Metallo-beta-Lactamse-6 (blaNDM-6)-producing Citrobacter werkmanii.
    Int J Antimicrob Agents. 2019;53:703-704.
    PubMed     Text format    


    April 2019
  5. BASSETTI M, Castaldo N, Cattelan A, Mussini C, et al
    Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
    Int J Antimicrob Agents. 2019;53:408-415.
    PubMed     Text format     Abstract available


    February 2019
  6. QUEK WM, Teng CB, Tan YZ, Chong K, et al
    Outcomes of Fosfomycin Use in Ceftriaxone-Resistant Enterobacteriaceae Urinary Tract Infection in the Elderly.
    Int J Antimicrob Agents. 2019;53:195-196.
    PubMed     Text format    


    October 2018
  7. ZHONG H, Zhao XY, Zhang ZL, Gu ZC, et al
    Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2018;52:443-450.
    PubMed     Text format     Abstract available


    September 2018
  8. MCKINNON J, Roy Chowdhury P, Djordjevic SP
    Genomic analysis of multidrug-resistant Escherichia coli ST58 causing urosepsis.
    Int J Antimicrob Agents. 2018;52:430-435.
    PubMed     Text format     Abstract available


    August 2018
  9. LISHMAN H, Costelloe C, Hopkins S, Johnson AP, et al
    Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antibiotic resistance: an ecological study.
    Int J Antimicrob Agents. 2018 Aug 23. pii: S0924-8579(18)30239.
    PubMed     Text format     Abstract available


  10. CHUANG L, Ratnayake L
    Overcoming challenges of treating extensively drug-resistant Acinetobacter baumannii bacteraemic urinary tract infection.
    Int J Antimicrob Agents. 2018 Aug 3. pii: S0924-8579(18)30207.
    PubMed     Text format    


    July 2018
  11. BOUXOM H, Fournier D, Bouiller K, Hocquet D, et al
    Which non-carbapenem antibiotics are active against extended-spectrum beta-lactamase-producing Enterobacteriaceae?
    Int J Antimicrob Agents. 2018;52:100-103.
    PubMed     Text format     Abstract available


  12. GIUFRE M, Errico G, Accogli M, Monaco M, et al
    Emergence of NDM-5-producing Escherichia coli sequence type 167 clone in Italy.
    Int J Antimicrob Agents. 2018;52:76-81.
    PubMed     Text format     Abstract available


    June 2018
  13. DEMONCHY E, Courjon J, Ughetto E, Durand M, et al
    Cefoxitin-based antibiotic therapy for extended-spectrum beta-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
    Int J Antimicrob Agents. 2018;51:836-841.
    PubMed     Text format     Abstract available


    April 2018
  14. MENDES RE, Castanheira M, Woosley LN, Stone GG, et al
    Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and
    Int J Antimicrob Agents. 2018 Apr 11. pii: S0924-8579(18)30103.
    PubMed     Text format     Abstract available


    March 2018
  15. XIAO AJ, Huntington JA, Long J, Caro L, et al
    Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Int J Antimicrob Agents. 2018 Mar 26. pii: S0924-8579(18)30075.
    PubMed     Text format     Abstract available


  16. BOUSQUET A, Bugier S, Larreche S, Bigaillon C, et al
    Clinical isolates of Escherichia coli solely resistant to mecillinam: prevalence and epidemiology.
    Int J Antimicrob Agents. 2018;51:493-497.
    PubMed     Text format     Abstract available


    February 2018
  17. SEIFERT H, Korber-Irrgang B, Kresken M
    In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Int J Antimicrob Agents. 2018;51:227-234.
    PubMed     Text format     Abstract available


    January 2018
  18. GARCIA-CASTILLO M, Garcia-Fernandez S, Gomez-Gil R, Pitart C, et al
    Activity of ceftazidime-avibactam against carbapenemase-producing enterobacteriaceae from urine samples obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    Int J Antimicrob Agents. 2018 Jan 22. pii: S0924-8579(18)30014.
    PubMed     Text format     Abstract available


    October 2017
  19. SOBKE A, Makarewicz O, Baier M, Bar C, et al
    Empiric treatment of lower urinary tract infections in the face of spreading multi-drug resistance: in vitro study of nitroxoline effectiveness.
    Int J Antimicrob Agents. 2017 Oct 27. pii: S0924-8579(17)30374.
    PubMed     Text format     Abstract available


    September 2017
  20. KIM SA, Altshuler J, Paris D, Fedorenko M, et al
    Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase producing enterobacteriaceae.
    Int J Antimicrob Agents. 2017 Sep 21. pii: S0924-8579(17)30353.
    PubMed     Text format     Abstract available


    June 2017
  21. CHIEN JY, Yu CJ, Hsueh PR
    High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan.
    Int J Antimicrob Agents. 2017 Jun 28. pii: S0924-8579(17)30207.
    PubMed     Text format     Abstract available


  22. SHAH KJ, Cherabuddi K, Shultz J, Borgert S, et al
    Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin resistant enterococcus spp (VRE): a single-center university hospital experience.
    Int J Antimicrob Agents. 2017 Jun 27. pii: S0924-8579(17)30218.
    PubMed     Text format     Abstract available


  23. MEZZATESTA ML, La Rosa G, Maugeri G, Zingali T, et al
    In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Int J Antimicrob Agents. 2017;49:763-766.
    PubMed     Text format     Abstract available


    May 2017
  24. BOURDELLON L, Thilly N, Fougnot S, Pulcini C, et al
    Impact of selective reporting of antibiotic susceptibility test results on the appropriateness of antibiotics chosen by french general practitioners in urinary tract infections: a randomised controlled case-vignette study.
    Int J Antimicrob Agents. 2017 May 31. pii: S0924-8579(17)30173.
    PubMed     Text format     Abstract available


  25. BOIX-PALOP L, Xercavins M, Badia C, Obradors M, et al
    Emerging extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
    Int J Antimicrob Agents. 2017 May 24. pii: S0924-8579(17)30170.
    PubMed     Text format     Abstract available


    April 2017
  26. BI W, Li B, Song J, Hong Y, et al
    Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum beta-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Int J Antimicrob Agents. 2017 Apr 26. pii: S0924-8579(17)30135.
    PubMed     Text format     Abstract available


    November 2016
  27. GUET-REVILLET H, Tomini E, Emirian A, Join-Lambert O, et al
    Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Int J Antimicrob Agents. 2016 Nov 15. pii: S0924-8579(16)30334.
    PubMed     Text format     Abstract available


    July 2016
  28. GRAU S, Luque S, Echeverria-Esnal D, Sorli L, et al
    Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.
    Int J Antimicrob Agents. 2016 Jul 5. pii: S0924-8579(16)30148.
    PubMed     Text format     Abstract available


  29. WANG LH, Liu PP, Wei DD, Liu Y, et al
    Clinical isolates of uropathogenic Escherichia coli ST131 producing NDM-7 metallo-beta-lactamase in China.
    Int J Antimicrob Agents. 2016;48:41-5.
    PubMed     Text format     Abstract available


    June 2016
  30. VAN DER MEE-MARQUET N, Diene SM, Chopin F, Goudeau A, et al
    Enigmatic occurrence of NDM-7 enzyme in the community.
    Int J Antimicrob Agents. 2016;47:505-7.
    PubMed     Text format    


    May 2016
  31. VEVE MP, Wagner JL, Kenney RM, Grunwald JL, et al
    Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections.
    Int J Antimicrob Agents. 2016 May 12. pii: S0924-8579(16)30092.
    PubMed     Text format     Abstract available


    April 2016
  32. ZMARLICKA MT, Cardwell SM, Crandon JL, Nicolau DP, et al
    Evaluation of a disease state management guideline for urinary tract infection.
    Int J Antimicrob Agents. 2016 Apr 22. pii: S0924-8579(16)30051.
    PubMed     Text format     Abstract available


  33. LOB SH, Hoban DJ, Sahm DF, Badal RE, et al
    Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.
    Int J Antimicrob Agents. 2016;47:317-23.
    PubMed     Text format     Abstract available


    February 2016
  34. JEAN SS, Coombs G, Ling T, Balaji V, et al
    Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.
    Int J Antimicrob Agents. 2016 Feb 17. pii: S0924-8579(16)00042.
    PubMed     Text format     Abstract available


    July 2015
  35. ROGER C, Nucci B, Molinari N, Bastide S, et al
    Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
    Int J Antimicrob Agents. 2015;46:21-7.
    PubMed     Text format     Abstract available


    April 2015
  36. ROGERS BA, Ingram PR, Runnegar N, Pitman MC, et al
    Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand.
    Int J Antimicrob Agents. 2015;45:351-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Urinary Tract Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: